Making Personalized Cancer Vaccines Accessible Alone & in Combination

• Preliminary data suggest that personalized cancer vaccines can be safe, effective at generating durable immunity, and possibly clinically effective in the adjuvant setting
• A major challenge, however, is cost and scalability
• Completely re-crafting the manufacturing process offers a way forward

Speakers:

Ira Mellman

Co-Founder & Chief Scientific Officer

Medici Therapeutics